ClinicalTrials.gg

Program

Ticagrelor

Also written as “ticagrelor”, “AZD6140” and “Ticagrelor Tablets”.

Its studies are mostly in Acute Coronary Syndrome · Coronary Artery Disease · Anemia, Sickle Cell · Vaso-Occlusive Crises · Ischemic Attack, Transient, led by 3 companies.

Furthest: phase 4, since Apr 19, 201144 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca410 open or runningphase 4since Apr 19, 2011Oct 23, 2006none ahead
Boehringer Ingelheim20 open or runningphase 1since May 9, 2012May 9, 2012none ahead
Johnson & Johnson10 open or runningphase 2since Nov 13, 2014Nov 13, 2014none ahead

Also a collaborator on its studies: parexel, iqvia-pty-ltd and Bayer.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 29 studies since Oct 23, 2006.

  1. Jan 14, 2014Phase 4 study in Non-ST Elevation Acute Coronary SyndromeAstraZeneca · NCT02052635 · 34 enrolled · United States
  2. Feb 12, 2014Phase 4 study in Stable Coronary Heart Disease (CHD)AstraZeneca · NCT02064985 · 61 enrolled · China
  3. Apr 22, 2014Phase 4 study in Peripheral Arterial DiseaseAstraZeneca · NCT02121288
  4. Aug 8, 20142 phase 2 studiesAstraZeneca · NCT02214121, NCT02227368
  5. Nov 13, 2014Johnson & Johnson's first study: phase 2 study in Acute Coronary SyndromeNew to Johnson & JohnsonJohnson & Johnson · NCT02293395 · 3,037 enrolled · United States, Argentina, Australia and more
  6. Mar 19, 2015Phase 4 study in Non-ST Elevated Myocardial InfarctionAstraZeneca · NCT02406248 · 108 enrolled · Taiwan
  7. Jun 17, 2015Phase 2 study in Anemia, Sickle CellAstraZeneca · NCT02482298 · 87 enrolled · United States, Egypt, France and more
  8. Apr 20, 2017Phase 1 study in Anemia, Sickle CellAstraZeneca · NCT03126695 · 44 enrolled · Germany
  9. Nov 20, 2017Phase 3 study in Ischemic Attack, TransientAstraZeneca · NCT03354429 · 11,016 enrolled · Argentina, Australia, Belgium and more
  10. Mar 16, 2018Phase 1 study in Anemia, Sickle CellAstraZeneca · NCT03492931 · 21 enrolled · Belgium, Italy, Kenya and more
  11. Jun 22, 2018Phase 3 study in Anemia, Sickle CellAstraZeneca · NCT03615924 · 193 enrolled · United States, Belgium, Brazil and more
  12. Feb 4, 2020Phase 3 study in Anemia, Sickle CellAstraZeneca · NCT04293172
  13. Oct 9, 2020Phase 1 study in Cardiovascular DiseasesAstraZeneca · NCT04588727 · 103 enrolled · United States
  14. Aug 2, 2024Phase 1 study in Healthy ParticipantsAstraZeneca · NCT06554821 · 28 enrolled · Germany

TargetBeta

P2RY12 →read by rule
“Purinergic receptor P2Y12 negative allosteric modulator”ChEMBL 37, by rule

Other programs on P2RY12

ProgramCompanyFurthest phaseStudies
ClopidogrelruleSanofiphase 471
selatogrelruleViatrisphase 311

Studies

All 44 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06554821Healthy Participants · Germany1CompletedAstraZenecaOct 8, 202428
NCT04588727Cardiovascular Diseases · United States1CompletedAstraZenecaJan 19, 2022103
NCT04293172Anemia, Sickle Cell3WithdrawnAstraZenecaOct 10, 20220
NCT03615924Anemia, Sickle Cell · United States, Belgium, Brazil and more3TerminatedAstraZenecaAug 13, 2020193
NCT03492931Anemia, Sickle Cell · Belgium, Italy, Kenya and more1CompletedAstraZenecaMay 7, 201921
NCT03354429Ischemic Attack, Transient · Argentina, Australia, Belgium and more3CompletedAstraZenecaDec 13, 201911,016
NCT03126695Anemia, Sickle Cell · Germany1CompletedAstraZenecaJul 24, 201744
NCT02482298Anemia, Sickle Cell · United States, Egypt, France and more2CompletedAstraZenecaNov 16, 201687
NCT02406248Non-ST Elevated Myocardial Infarction · Taiwan4CompletedAstraZenecaFeb 9, 2017108
NCT02293395Acute Coronary Syndrome · United States, Argentina, Australia and more2CompletedJohnson & JohnsonOct 14, 20163,037
NCT02227368Peripheral Arterial Disease · United States2TerminatedAstraZenecaMay 23, 201640
NCT02214121Anemia, Sickle Cell · United States, Canada, Kenya and more2CompletedAstraZenecaFeb 27, 201746
NCT02121288Peripheral Arterial Disease4WithdrawnAstraZenecaFeb 20160
NCT02064985Stable Coronary Heart Disease (CHD) · China4CompletedAstraZenecaNov 201461
NCT02052635Non-ST Elevation Acute Coronary Syndrome · United States4TerminatedAstraZenecaApr 201534
NCT02022748Kidney Failure, Chronic · United States1CompletedAstraZenecaMay 9, 201627
NCT01994720Ischemic Attack, Transient · United States, Argentina, Australia and more3CompletedAstraZenecaMar 2, 201613,307
NCT01991795Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more3CompletedAstraZenecaJan 25, 201919,271
NCT01887626Bioavailability Heathy Volunteers · United Kingdom1CompletedAstraZenecaSep 201336
NCT01870921Acute Coronary Syndrome · China4CompletedAstraZenecaSep 30, 20152,004
NCT01864005Non-ST or ST Elevation Acute Coronary Syndromes · China4CompletedAstraZenecaMar 201460
NCT01757262Coronary Disease3WithdrawnAstraZenecaApr 20130
NCT01744288Inhibition on Platelet Aggregation · United States1CompletedAstraZenecaApr 2014258
NCT01732822Peripheral Arterial Disease · United States, Argentina, Brazil and more3CompletedAstraZenecaSep 26, 201613,885
NCT01734772Healthy · Germany1CompletedBoehringer IngelheimJun 201348
NCT01603082Acute Coronary Syndrome · United States4CompletedAstraZenecaJun 2014343
NCT01595854Healthy · Germany1CompletedBoehringer IngelheimJun 201236
NCT01588626Healthy · Japan1CompletedAstraZenecaJun 201212
NCT01523392Stable Coronary Artery Disease · United States4CompletedAstraZenecaSep 201350
NCT01523366Stable Coronary Artery Disease · United States4CompletedAstraZenecaMay 201353
NCT01504906Healthy · United States1CompletedAstraZenecaJun 201220
NCT01350921Drug Drug Interaction · United States, Sweden1CompletedAstraZenecaMar 201222
NCT01347580Myocardial Infarction · Algeria, Australia, Austria and more4CompletedAstraZenecaNov 20131,875
NCT01294462Acute Coronary Syndrome · Japan, Korea, Republic of, Taiwan3CompletedAstraZenecaJul 2012801
NCT01226602Blood Flow Speed · Sweden1CompletedAstraZenecaApr 201139
NCT01225562Myocardial Infarction · United States, Argentina, Australia and more3CompletedAstraZenecaDec 201421,379
NCT01118325Stable Coronary Artery Disease · Japan, Philippines2CompletedAstraZenecaMar 2011146
NCT00738842Gout1CompletedAstraZenecaJul 200824
NCT00733265Renal Insufficiency · United States1CompletedAstraZenecaSep 200824
NCT00721448Pharmacokinetics · China1CompletedAstraZenecaAug 200824
NCT00685906Healthy · United States1CompletedAstraZenecaOct 200824
NCT00642811Coronary Artery Disease · United States, Canada, Denmark and more2CompletedAstraZenecaMar 200998
NCT00528411Coronary Artery Disease · United States, United Kingdom2CompletedAstraZenecaMar 2009123
NCT00391872Acute Coronary Syndrome · United States, Argentina, Australia and more3CompletedAstraZenecaMar 200918,624

How it is read

Names in the registry

  • “Ticagrelor”, 24 entries
  • “ticagrelor”, 10 entries
  • “AZD6140”, 7 entries
  • “Ticagrelor Tablets”, 3 entries
  • “Ticagrelor 60 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.